{
    "id": "46843228",
    "text": "Pharmacyclics LLC is an American biopharmaceutical company based in Sunnyvale, California. It is primarily focused on the development of cancer therapies. In 2017, Xynomic Pharmaceuticals acquired all global rights to Abexinostat, Pharmacyclics' primary commercial product. ==Acquisition by AbbVie== In March 2015, Chicago-based biopharmaceutical firm AbbVie announced it would acquire Pharmacyclics, as well as its lead anti-cancer compound ibrutinib (Imbruvica) for $21 billion. As part of the deal, AbbVie will pay $261.25 per share in a mixture of both cash and AbbVie equity. The merger is expected to close in mid-2015.https://www.sec.gov/Archives/edgar/data/949699/000119312515079014/d885940dex991.htm Duggan will receive over $3.55 billion from the sale of Pharmacyclics to AbbVie in \"one of the biggest paydays ever from the buyout of a publicly held company.\" As CEO and Chairman of Pharmacyclics since 2008, Robert Duggan has opted not to receive compensation from the company. ==References== ==External links== * Category:AbbVie Category:Biotechnology companies of the United States Category:Companies based in Sunnyvale, California Category:Pharmaceutical companies established in 1991 Category:Orphan drug companies Category:Companies formerly listed on NASDAQ Category:1991 establishments in California Category:2015 mergers and acquisitions Category:Corporate subsidiaries ",
    "title": "Pharmacyclics"
}